Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Labopharm enters into US$25 million standby equity distribution agreement with YA Global Master

Reading Time 1 minute read Subscribe



Labopharm Inc.

On November 25, 2009, Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) announced that it had entered into a standby equity distribution agreement (SEDA) with YA Global Master SPV Ltd., a fund managed by Yorkville Advisors, LLC. Under the terms of the agreement, YA has committed to provide up to $25 million of capital during the next three years, at Labopharm's discretion, through the purchase of newly issued Labopharm common shares. In connection with the SEDA, Labopharm will file a preliminary short-form base shelf prospectus with the securities authorities in each province and territory of Canada and a corresponding registration statement with the United States Securities and Exchange Commission. These filings, when made final or effective, will allow Labopharm to qualify the shares issued under the SEDA and make offerings of common shares, preferred shares, warrants or combination thereof for an amount of up to $100 million during the next 25 months. Labopharm was advised in the negotiation of the SEDA by Frédéric Despars, Vice-President, General Counsel and Corporate Secretary and by Fasken Martineau with a team led by Louis-François Hogue and that included, among others, Frédéric Boucher, Jean Michel Lapierre and Caitlin Rose.



    Receive email updates from our team